KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

Alnylam Pharmaceuticals (ALNY) Shares Issued (2016 - 2025)

Historic Shares Issued for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to $41.7 million.

  • Alnylam Pharmaceuticals' Shares Issued rose 1494.85% to $41.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $250.0 million, marking a year-over-year decrease of 1746.92%. This contributed to the annual value of $250.0 million for FY2025, which is 1746.92% down from last year.
  • Alnylam Pharmaceuticals' Shares Issued amounted to $41.7 million in Q4 2025, which was up 1494.85% from $77.7 million recorded in Q3 2025.
  • Alnylam Pharmaceuticals' 5-year Shares Issued high stood at $153.0 million for Q3 2022, and its period low was $22.5 million during Q2 2022.
  • Moreover, its 5-year median value for Shares Issued was $48.2 million (2021), whereas its average is $60.3 million.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Shares Issued tumbled by 8378.97% in 2023, and later skyrocketed by 33554.12% in 2024.
  • Alnylam Pharmaceuticals' Shares Issued (Quarter) stood at $45.0 million in 2021, then grew by 25.92% to $56.7 million in 2022, then tumbled by 45.53% to $30.9 million in 2023, then grew by 17.43% to $36.3 million in 2024, then grew by 14.95% to $41.7 million in 2025.
  • Its Shares Issued was $41.7 million in Q4 2025, compared to $77.7 million in Q3 2025 and $81.2 million in Q2 2025.